Current Atherosclerosis Reports

, Volume 8, Issue 3, pp 219–222 | Cite as

Clinical trials report

  • Robert S. Rosenson
Article

Keywords

Statin Therapy Coronary Heart Disease Event Coronary Heart Disease Patient Coronary Heart Disease Death Heart Protection Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosenson RS: New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. Curr Probl Cardiol 2005, In press.Google Scholar
  2. 2.
    Expert panel on detection, evaluation and treatment of high blood cholesterol in adults: National Cholesterol Education Program (NCEP): third report of the expert panel on detection, evaluation and treatment of high blood cholesterol (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.CrossRefGoogle Scholar
  3. 3.
    DeBacker G, Ambrosini E, Borch-Johnsen K, et al.: European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003, 24:1601–1610.CrossRefGoogle Scholar
  4. 4.
    Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.PubMedCrossRefGoogle Scholar
  5. 5.
    Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003, 361:2005–2016.CrossRefGoogle Scholar
  6. 6.
    Colhoun H, Betteridge D, Durrington P, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685–696.PubMedCrossRefGoogle Scholar
  7. 7.
    Sever P, Dahlöf B, Poulter N, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149–1158.PubMedCrossRefGoogle Scholar
  8. 8.
    Haffner S, Alexander C, Cook T, et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses of the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999, 159:2661–2667.PubMedCrossRefGoogle Scholar
  9. 9.
    Goldberg R, Mellies M, Sacks F, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation 1998, 98:2513–2519.PubMedGoogle Scholar
  10. 10.
    The Long-Term Investigaton with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravasztatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357.CrossRefGoogle Scholar
  11. 11.
    Rubins HB, Robins SJ, Collins D, et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597–2604.PubMedCrossRefGoogle Scholar
  12. 12.
    The FIELD Study Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus: randomised controlled trial. Lancet 2005, 366:1849–1861.CrossRefGoogle Scholar
  13. 13.
    Shepherd J, on behalf of the TNT Diabetes Subcommittee and the TNT Steering Committee: Paper presented at the Annual Meeting of the American Diabetes Association. San Diego, CA, June 13, 2005. Webcast available at http://webcasts.prous.com/ada2005. Accessed August 1, 2005.Google Scholar
  14. 14.
    Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85:37–45.PubMedGoogle Scholar
  15. 15.
    The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000, 102:21–27.Google Scholar
  16. 16.
    Rosenson R: Current overview of statin-induced myopathy. Am J Med 2004, 116:405–416.CrossRefGoogle Scholar
  17. 17.
    Rosenson RS, Lowe GD: Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998, 140:271–280.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Robert S. Rosenson

There are no affiliations available

Personalised recommendations